Menu
Search
|

Menu

Close
X

Chembio Diagnostics Inc CEMI.OQ (NASDAQ Stock Exchange Capital Market)

7.35 USD
-- (--)
As of 2:29 AM IST
chart
Previous Close 7.35
Open --
Volume --
3m Avg Volume 5,709
Today’s High --
Today’s Low --
52 Week High 9.20
52 Week Low 5.05
Shares Outstanding (mil) 12.31
Market Capitalization (mil) 77.55
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.50 Mean rating from 2 analysts

KEY STATS

Revenue (mm, USD)
FY17
18
FY16
18
FY15
24
EPS (USD)
FY17
-0.356
FY16
-1.299
FY15
-0.249
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
4.21
5.77
Price to Book (MRQ)
vs sector
5.03
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
0.00
16.52
LT Debt to Equity (MRQ)
vs sector
0.00
12.22
Return on Investment (TTM)
vs sector
-68.16
14.43
Return on Equity (TTM)
vs sector
-69.09
16.13

EXECUTIVE LEADERSHIP

Katherine Davis
Non-Executive Independent Chairman of the Board, Since 2014
Salary: --
Bonus: --
John Sperzel
President, Chief Executive Officer, Director, Since 2017
Salary: $298,558.00
Bonus: --
Neil Goldman
Chief Financial Officer, Executive Vice President, Since 2017
Salary: --
Bonus: --
Sharon Klugewicz
President - Americas Region, Since 2017
Salary: $259,616.00
Bonus: $75,000.00
Javan Esfandiari
Chief Science and Technology Officer, Since 2015
Salary: $315,000.00
Bonus: $90,000.00

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

3661 Horseblock Rd
MEDFORD   NY   11763-2215

Phone: +1631.9241135
Site: chembio.com/

Chembio Diagnostics, Inc. (Chembio), and its subsidiary, Chembio Diagnostic Systems, Inc., develop, manufacture, market and license rapid point-of-care diagnostic tests (POCTs) that detect infectious diseases. The Company's products available are rapid tests for the detection of human immunodeficiency virus (HIV) 1/2 antibodies, and a multiplex rapid test for the detection of HIV and Syphilis antibodies. The HIV 1/2 rapid tests employ in-licensed and lateral flow technologies that are used with all blood matrices as samples, and are manufactured in a standard cassette format, a dipstick format and a barrel format. Its HIV 1/2 rapid antibody detection test incorporates the Dual Path Platform (DPP) POCT technology. The DPP HIV 1/2 Assay detects antibodies to HIV 1 and 2 in oral fluid samples, as well as in all blood matrices. The Company's product pipeline includes a multiplex rapid test for earlier detection of HIV and a multiplex test that detects HIV and Syphilis specific antibodies.

SPONSORED STORIES